TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9643595

Group type: EXPERIMENTAL
Intervention: No alteration of anticoagulant treatment (study group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Warfarin treatment stopped for 2-3 days (control group)
Number of subjects: 65
Study: 7897766

Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Traditional uvulopalatopharyngoplasty (UPPP)
Number of subjects: 741
Study: 2958366

Group type: EXPERIMENTAL
Intervention: Gamete intrafallopian transfer (GIFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro fertilization (IVF) and embryo transfer (ET)
Number of subjects: 0
Study: 30782352

Group type: EXPERIMENTAL
Intervention: Guided Internet-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention only (control condition)
Number of subjects: 0
Study: 27890713

Group type: EXPERIMENTAL
Intervention: Single IV infusion of 20, 100, or 200 × 10^6 human bone marrow-derived mesenchymal stem cells
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single IV infusion of human mesenchymal stem cells
Number of subjects: 9
Study: 25872928

Group type: EXPERIMENTAL
Intervention: DESMOND‐ID programme
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 23700134

Group type: EXPERIMENTAL
Intervention: Home exercise bike training with telemonitoring
Number of subjects: 23
Study: 21311063

Group type: EXPERIMENTAL
Intervention: New risk model incorporating age, diastolic blood pressure, high-sensitivity C-reactive protein, homocysteine, waist-to-hip ratio, and self-reported health status.
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: Age >85 years
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure <70 mm Hg
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein >3 mg/L
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: Homocysteine >15 umol/L
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio >1
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: Fair or poor self-reported health
Number of subjects: 4382

Group type: COMPARATOR
Intervention: Traditional risk factors (age, smoking)
Number of subjects: 4382

Group type: EXPERIMENTAL
Intervention: Overall rate of stroke/MI
Number of subjects: 4382
Study: 19752338

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 6092

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 6092
Study: 17418554

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Montelukast 5mg once daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Montelukast 5mg once daily (second month)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily (second month)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily (first and second month)
Number of subjects: 48
Study: 15145911

Group type: EXPERIMENTAL
Intervention: Treatment to below 140/90 mm Hg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of blood pressure levels
Number of subjects: 0
Study: 11304898

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 1 mg/kg loading infusion over 30 minutes followed by 1 mg/kg/day continuous i.v. infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) in ARDS patients
Number of subjects: 20
Study: 9789204

Group type: EXPERIMENTAL
Intervention: 0.006 mg/kg apomorphine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.012 mg/kg apomorphine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 28
Study: 7990664

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (homozygotes)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Obligate heterozygotes (parents of CF patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 113
Study: 2657045

Group type: EXPERIMENTAL
Intervention: Oral ritodrine (20 mg every four hours)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oral terbutaline (5 mg every four hours)
Number of subjects: 102
Study: 29795365

Group type: EXPERIMENTAL
Intervention: Lottery-based incentive
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Direct incentive
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control (daily self‐weighing and text messaging feedback)
Number of subjects: 191
Study: 25927849

Group type: EXPERIMENTAL
Intervention: SGJP granules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23488491

Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study: 21609169

Group type: EXPERIMENTAL
Intervention: STI role play simulation teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no role-play teaching)
Number of subjects: 0
Study: 19141661

Group type: EXPERIMENTAL
Intervention: Monthly home visits from trained volunteers over a 9‐month period
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard professional care only
Number of subjects: 312
Study: 16454834

Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2b (100 microg/wk) + lamivudine (100 mg/day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Peg-interferon alpha-2b (100 microg/wk) + placebo
Number of subjects: 266
Study: 15237079

Group type: EXPERIMENTAL
Intervention: Algorithm-guided treatment (ALGO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 11244136

Group type: EXPERIMENTAL
Intervention: 12-mm Finn Chamber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Webril pad
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-mm Finn Chamber
Number of subjects: 0
Study: 10322844

Group type: EXPERIMENTAL
Intervention: Fuganlin (FGL) oral liquid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antipyretic oral liquid (Control)
Number of subjects: 0
Study: 2017969

Group type: EXPERIMENTAL
Intervention: Dipyridamole-thallium stress testing
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isometric handgrip exercises added to dipyridamole imaging protocol
Number of subjects: 47
Study: 6817658

Group type: EXPERIMENTAL
Intervention: Inhaled cromoglycate
Number of subjects: 7

Group type: COMPARATOR
Intervention: No intervention (absence of inhaled cromoglycate)
Number of subjects: 7
Study: 31702402

Group type: EXPERIMENTAL
Intervention: Clonazepam 2 mg test tablet (Sanofi‐Aventis de Colombia S.A.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rivotril® (Produtos Roche Químicos e Farmacêuticos S.A.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 36
Study: 29326414

Group type: EXPERIMENTAL
Intervention: Debriefing based on the clinical judgment model
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual debriefing
Number of subjects: 48
Study: 26342812

Group type: EXPERIMENTAL
Intervention: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group A (previous radiotherapy)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group B (no previous radiotherapy)
Number of subjects: 46
Study: 23328908

Group type: EXPERIMENTAL
Intervention: Anodal cerebellar tDCS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham cerebellar tDCS
Number of subjects: 21
Study: 22070448

Group type: EXPERIMENTAL
Intervention: Self-efficacy, response efficacy, and mothers' concern
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Content analysis of mothers' open-ended reasons for concern
Number of subjects: 386
Study: 19224350

Group type: EXPERIMENTAL
Intervention: Consistent complainants reporting everyday events
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Consistent complainants reporting IPA
Number of subjects: 374

Group type: COMPARATOR
Intervention: Inconsistent complainants reporting everyday events
Number of subjects: 374

Group type: COMPARATOR
Intervention: Inconsistent complainants reporting IPA
Number of subjects: 374
Study: 17182417

Group type: EXPERIMENTAL
Intervention: Patient-rated alliance
Number of subjects: 356

Group type: COMPARATOR
Intervention: Therapist-rated alliance
Number of subjects: 356

Group type: COMPARATOR
Intervention: Patient alliance ratings
Number of subjects: 356

Group type: COMPARATOR
Intervention: Therapist alliance ratings
Number of subjects: 356
Study: 15622016

Group type: EXPERIMENTAL
Intervention: Symptomatic Huntington's disease patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymptomatic gene-positive Huntington's disease patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall HD group (symptomatic and asymptomatic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counting in 1's
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subset of patients and controls retested after 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11250974

Group type: EXPERIMENTAL
Intervention: 30 mg lefradafiban three times daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 45 mg lefradafiban three times daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 60 mg lefradafiban three times daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 9827736

Group type: EXPERIMENTAL
Intervention: MDI-spacer (salbutamol delivered via metered-dose inhaler plus spacer, 2.4 mg/h, 4 puffs at 10-minute intervals for 3 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: NEB (nebulized salbutamol, 6 mg/h, 1.5 mg at 15-minute intervals for 3 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MDI-spacer
Number of subjects: 100

Group type: COMPARATOR
Intervention: NEB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 10150549

Group type: EXPERIMENTAL
Intervention: Early total enteral nutrition (TEN) with propofol sedation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) with midazolam sedation
Number of subjects: 45
Study: 2899511

Group type: EXPERIMENTAL
Intervention: Alprenolol (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 29503004

Group type: EXPERIMENTAL
Intervention: cBMA (concentrated bone marrow aspirate)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 26754759

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of beta-lactam antibiotics
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intermittent bolus (IB) dosing of beta-lactam antibiotics
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) and Intermittent bolus (IB) dosing
Number of subjects: 140
Study: 25757947

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23347503

Group type: EXPERIMENTAL
Intervention: Support program (intervention)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2082
Study: 21913408

Group type: EXPERIMENTAL
Intervention: reamberin (800 ml/day for 8 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 18489503

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccination
Number of subjects: 7861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7861
Study: 16458252

Group type: EXPERIMENTAL
Intervention: 6-session healthy dieting intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waitlist condition (control)
Number of subjects: 85
Study: 12740734

Group type: EXPERIMENTAL
Intervention: Incremental test on treadmill (TR) starting speed 6 or 8 km x h ‐1, increments 2 km x h ‐1 every 3 min
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Incremental test on bicycle ergometer (BE) starting at 50 Watt, increments 25 or 50 Watt every 3 min
Number of subjects: 371
Study: 10780124

Group type: EXPERIMENTAL
Intervention: Active Nicotine Patch
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Mint Snuff
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo Patch
Number of subjects: 402

Group type: COMPARATOR
Intervention: No Mint Snuff
Number of subjects: 402
Study: 8694014

Group type: EXPERIMENTAL
Intervention: HMCT formula (46 mol% 8:0 + 10:0)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LMCT formula (4.8 mol% 8:0 + 10:0)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HMCT formula
Number of subjects: 20
Study: 8398824

Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase (STK) < 6 U/l
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase (STK) > 11 U/l
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Melphalan treatment
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: ABCM treatment (adriamycin, BCNU, cyclophosphamide and melphalan)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Low STK and SB2M
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: High STK and SB2M
Number of subjects: 547
Study: 3095558

Group type: EXPERIMENTAL
Intervention: Central venous parenteral nutrition (TPN)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Enteral nutrition by jejunostomy (Jej)
Number of subjects: 46
Study: 29617504

Group type: EXPERIMENTAL
Intervention: Roller pump (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (G2)
Number of subjects: 60
Study: 27807041

Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED) (15% energy from almonds)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nut-free diet (NFD)
Number of subjects: 86
Study: 24032716

Group type: EXPERIMENTAL
Intervention: Balance training on the Biodex balance system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy exercise program
Number of subjects: 30
Study: 23748506

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 1379
Study: 21963124

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted socket suspension system (VASS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pin lock suspension system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 20
Study: 19033573

Group type: EXPERIMENTAL
Intervention: Pelvic systematic lymphadenectomy
Number of subjects: 514

Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 514
Study: 17010864

Group type: EXPERIMENTAL
Intervention: Stop-and-chop
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nuclear preslice
Number of subjects: 43
Study: 14506404

Group type: EXPERIMENTAL
Intervention: Short Index of Problems (SIP)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Short Index of Problems (SIP) subscales
Number of subjects: 153
Study: 10764703

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for one week (H pylori eradication group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 12 months (H pylori positive group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No treatment (H pylori negative control group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: H pylori positive patients who remained H pylori positive (persistently H pylori positive group)
Number of subjects: 83
Study: 8834976

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg at bedtime
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1349028

Group type: COMPARATOR
Intervention: TRZ alone (5.0 mg)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: TRZ+MCTZ-2.5 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: TRZ+MCTZ-5.0 mg
Number of subjects: 222
Study: 6146258

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists
Number of subjects: 0
Study: 30654675

Group type: EXPERIMENTAL
Intervention: Active TENS2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other TENS groups
Number of subjects: 10
Study: 31475572

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 29159864

Group type: EXPERIMENTAL
Intervention: Music intervention for 30 minutes during daytime rest
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (rest without music)
Number of subjects: 37
Study: 26982282

Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cream (for infants with BPD)
Number of subjects: 75
Study: 24479699

Group type: EXPERIMENTAL
Intervention: Text-based message with percentages
Number of subjects: 323

Group type: COMPARATOR
Intervention: Bar graph with percentages
Number of subjects: 323

Group type: COMPARATOR
Intervention: Combined form
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Exposure to a message about genetically modified foods
Number of subjects: 323
Study: 23386239

Group type: EXPERIMENTAL
Intervention: Single umbilical incision appendectomy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 184
Study: 21105887

Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin for 3 days (U group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 4-week levofloxacin-azithromycin combination (P group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sequential treatment with both azithromycin and 4-week levofloxacin-azithromycin (U+P group)
Number of subjects: 55
Study: 18599162

Group type: EXPERIMENTAL
Intervention: Blended learning program (including e-learning) administered to 26 new nurses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Face-to-face instruction in the classroom given to 24 new nurses
Number of subjects: 50
Study: 15686240

Group type: EXPERIMENTAL
Intervention: Standard Gamma nail (SGN)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Medoff sliding plate (MSP)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both SGN and MSP
Number of subjects: 217
Study: 12188171

Group type: EXPERIMENTAL
Intervention: Topical glaucoma medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10711075

Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (regular insulin)
Number of subjects: 51
Study: 7574775

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of methotrexate (MTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraarterial (IA) administration of MTX
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of MTX
Number of subjects: 20
Study: 2322054

Group type: EXPERIMENTAL
Intervention: Intraoperative plasmapheresis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 71943

Group type: EXPERIMENTAL
Intervention: COMB (cyclophosphamide, vincristine, methyl CCNU, and bleomycin)
Number of subjects: 47

Group type: COMPARATOR
Intervention: CTX (cyclophosphamide alone)
Number of subjects: 47
Study: 29709431

Group type: EXPERIMENTAL
Intervention: Midwife-led counselling
Number of subjects: 27
Study: 28024930

Group type: EXPERIMENTAL
Intervention: Urine α1‐microglobulin (A1M)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein 1 (MCP‐1)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Urine procollagen type III and type I
Number of subjects: 491
Study: 26076841

Group type: EXPERIMENTAL
Intervention: Xylaria nigripes
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 23866314

Group type: EXPERIMENTAL
Intervention: Red yeast rice (RYR) extract for 8 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Red yeast rice (RYR) extract
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21751861

Group type: EXPERIMENTAL
Intervention: High-volume (170 mL) ropivacaine (0.2%) with epinephrine (1:100,000)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 19504141

Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogensulfate (CHS, 300 mg loading, followed by 75 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB, 300 mg loading, followed by 75 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogensulfate (CHS, 5 micromol/L ADP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB, 5 micromol/L ADP)
Number of subjects: 21
Study: 16372176

Group type: EXPERIMENTAL
Intervention: ThermoWrap garment (water-filled garment)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care (warm air mattress with additional insulation)
Number of subjects: 22
Study: 15504308

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RAB) 10 mg
Number of subjects: 177

Group type: COMPARATOR
Intervention: Omeprazole (OME) 20 mg
Number of subjects: 177
Study: 11096461

Group type: EXPERIMENTAL
Intervention: vit C‐1500 (1500 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: vit C‐500 (500 mg/day)
Number of subjects: 29
Study: 9151231

Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT) using p-boronophenylalanine (BPA) at a dose of 250 mg BPA/kg body weight during a 2-hour infusion.
Number of subjects: 18
Study: 10146404

Group type: EXPERIMENTAL
Intervention: Resistive training program (3 days per week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise walking program (3 days per week for 12 weeks)
Number of subjects: 60
Study: 3533568

Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg X 5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 28914562

Group type: EXPERIMENTAL
Intervention: Regular aquatic exercise
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 452